General Director of the drug company “BioNTech” Ugur Shaheen announced that the start of distribution of the “Biontech / Pfizer” vaccine for the prevention of the emerging corona virus “Covid-19” is “possible” next month.
Before this exclusive statement to the French Press Agency, Shaheen said yesterday to Reuters TV that the US Food and Drug Administration may grant approval for the emergency use of the vaccine before the end of the first half of next month or at the beginning of the second half of the month.
Officials said that the US states and territories are ready to start distributing the vaccine within 24 hours of obtaining the necessary regulatory approval.
And officials said complicated storage requirements would not be a barrier to getting the vaccine for all Americans.
Pfizer and BioNTech said Wednesday that they may obtain approval from US and European regulatory agencies for the emergency use of their vaccine next month, after the results of the final experiments showed that the vaccine’s success rate is 95% and there are no serious side effects.
It was found that the effectiveness of the vaccine is stable in different age groups and ethnicities, which is a promising sign.
It is noteworthy that the success rate of the vaccine, which the American “Pfizer” and its German partner “Biontech” worked on, is the highest of any vaccine that has been tested in the last clinical stages so far, and experts say it is a great achievement in the race towards an end to the pandemic.
Shaheen added that it is possible to obtain conditional approval from the European Union in the second half of next December.
An informed source said that the US Food and Drug Administration’s Vaccine Advisory Committee plans to meet in principle from 8 to 10 December, but these dates are subject to change.
Pfizer said it expects to produce 50 million doses this year, sufficient to protect 25 million people, and then produce up to 1.3 billion doses in 2021.